{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=14",
    "query": {
      "intervention": "Placebo - saline",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 3542,
    "total_pages": 355,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+saline&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:43:55.889Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02063594",
      "title": "Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NCTX (PEGylated Liposomal Iodixanol Injection)",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marval Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-10",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02063594"
    },
    {
      "nct_id": "NCT06447194",
      "title": "Effect of RECK in Posterior Spinal Fusion",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Degenerative Lumbar Spinal Stenosis",
        "Degenerative Disc Disease",
        "Degenerative Spondylolisthesis",
        "Degenerative Disease"
      ],
      "interventions": [
        {
          "name": "Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-10-01",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06447194"
    },
    {
      "nct_id": "NCT03712345",
      "title": "Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Granulomatosis With Polyangiitis (GPA)",
        "Microscopic Polyangiitis (MPA)"
      ],
      "interventions": [
        {
          "name": "IFX-1 low dose",
          "type": "DRUG"
        },
        {
          "name": "IFX-1 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InflaRx GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-10-15",
      "completion_date": "2021-05-03",
      "has_results": true,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 33,
      "location_summary": "Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712345"
    },
    {
      "nct_id": "NCT02856854",
      "title": "A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "EMB-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cocaine IV",
          "type": "DRUG"
        },
        {
          "name": "Saline IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Embera NeuroTherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-07",
      "completion_date": "2017-07-25",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02856854"
    },
    {
      "nct_id": "NCT06897202",
      "title": "A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity in Diabetes",
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "MET097 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 133,
      "start_date": "2025-03-14",
      "completion_date": "2026-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 29,
      "location_summary": "Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06897202"
    },
    {
      "nct_id": "NCT07675629",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-09-01",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07675629"
    },
    {
      "nct_id": "NCT06193031",
      "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "C16TR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tyvaso®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-11-17",
      "completion_date": "2015-12-18",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06193031"
    },
    {
      "nct_id": "NCT05698095",
      "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Safety",
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "5-methoxy-N,N-dimethyltryptamine succinate salt",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Usona Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2022-12-27",
      "completion_date": "2023-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698095"
    },
    {
      "nct_id": "NCT06896136",
      "title": "Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diarrhea Infectious"
      ],
      "interventions": [
        {
          "name": "VENBETA6890",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Klempner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2025-02-11",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06896136"
    },
    {
      "nct_id": "NCT05997264",
      "title": "Anthrax AV7909 Boost Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AV7909 Full Dose (0.5 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909 Half Dose (0.25 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 220,
      "start_date": "2023-12-05",
      "completion_date": "2026-08-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-19T01:43:55.889Z",
      "location_count": 7,
      "location_summary": "Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more",
      "locations": [
        {
          "city": "Hickory",
          "state": "North Carolina"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Jefferson City",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997264"
    }
  ]
}